{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:57:37Z","timestamp":1782741457257,"version":"3.54.5"},"reference-count":132,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100004230","name":"Korea Polar Research Institute","doi-asserted-by":"publisher","award":["PAP 2018"],"award-info":[{"award-number":["PAP 2018"]}],"id":[{"id":"10.13039\/501100004230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1A2C1010766"],"award-info":[{"award-number":["NRF-2020R1A2C1010766"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2019 R1G1A1008566"],"award-info":[{"award-number":["NRF-2019 R1G1A1008566"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2021,2,9]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Gene therapy is one of the frontier fields of medical breakthroughs that poses as an effective\nsolution to previously incurable diseases. The delivery of the corrective genetic material or a\ntherapeutic gene into the cell restores the missing gene function and cures a plethora of diseases, incurable\nby the conventional medical approaches. This discovery holds the potential to treat many\nneurodegenerative disorders such as muscular atrophy, multiple sclerosis, Parkinson\u2019s disease (PD)\nand Alzheimer\u2019s disease (AD), among others. Gene therapy proves as a humane, cost-effective alternative\nto the exhaustive often arduous and timely impossible process of finding matched donors\nand extensive surgery. It also overcomes the shortcoming of conventional methods to cross the\nblood-brain barrier. However, the use of gene therapy is only possible after procuring the in-depth\nknowledge of the immuno-pathogenesis and molecular mechanism of the disease. The process of\ngene therapy can be broadly categorized into three main steps: elucidating the target gene, culling\nthe appropriate vector, and determining the best mode of transfer; each step mandating pervasive research.\nThis review aims to dissertate and summarize the role, various vectors and methods of delivery\nemployed in gene therapy with special emphasis on therapy directed at the central nervous\nsystem (CNS) associated with neurodegenerative diseases.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523220999200917114101","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T16:24:26Z","timestamp":1600446266000},"page":"11-22","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Exploring the Role of Gene Therapy for Neurological Disorders"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-058X","authenticated-orcid":true,"given":"Nidhi","family":"Puranik","sequence":"first","affiliation":[{"name":"Biological Science Department, Bharathiar University, Coimbatore, Tamil Nadu-641046, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4047-7236","authenticated-orcid":true,"given":"Dhananjay","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi Singh","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Amity Institute of Biotechnology, Amity University, Gwalior, Madhya Pradesh 474005, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minseok","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Pukyong National University, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-O","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fgene.2019.00868","volume":"10","author":"Shahryari A.","year":"2019","unstructured":"Shahryari A.; Saghaeian Jazi M.; Mohammadi S.; Razavi Nikoo H.; Nazari Z.; Hosseini E.S.; Development and clinical translation of gene therapy for genetic disorders. Front Genet 2019,10,868","journal-title":"Front Genet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"E538","DOI":"10.3390\/genes9110538","volume":"9","author":"Cooney A.L.","year":"2018","unstructured":"Cooney A.L.; McCray P.B.; Sinn P.L.; Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes (Basel) 2018,9(11),E538","journal-title":"Genes (Basel)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2174\/1566523219666190924121836","volume":"19","author":"Guo X-L.","year":"2019","unstructured":"Guo X-L.; Chung T-H.; Qin Y.; Zheng J.; Zheng H.; Sheng L.; Wynn T.; Chang L.J.; Hemophilia gene therapy: New development from bench to bed side. Curr Gene Ther 2019,19(4),264-273","journal-title":"Curr Gene Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ymthe.2017.03.018","volume":"25","author":"Thrasher AJ","year":"2017","unstructured":"Thrasher AJ; Williams DA; Evolving gene therapy in primary immunodeficiency. J Am Soc Gene Therap 2017,25(5),1132-41","journal-title":"J Am Soc Gene Therap"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.preteyeres.2018.08.003","volume":"68","author":"Lee J.H.","year":"2019","unstructured":"Lee J.H.; Wang J-H.; Chen J.; Li F.; Edwards T.L.; Hewitt A.W.; Liu G.S.; Gene therapy for visual loss: Opportunities and concerns. Prog Retin Eye Res 2019,68,31-53","journal-title":"Prog Retin Eye Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/ijms20225722","volume":"20","author":"Ziccardi L.","year":"2019","unstructured":"Ziccardi L.; Cordeddu V.; Gaddini L.; Matteucci A.; Parravano M.; Malchiodi-Albedi F.; Varano M.; Gene therapy in retinal dystrophies. Int J Mol Sci 2019,20(22),5722","journal-title":"Int J Mol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","volume":"127","author":"Hoban M.D.","year":"2016","unstructured":"Hoban M.D.; Orkin S.H.; Bauer D.E.; Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood 2016,127(7),839-848","journal-title":"Blood"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/ijns3020008","volume":"3","author":"Al-Zaidy S.A.","year":"2017","unstructured":"Al-Zaidy S.A.; Lloyd-Puryear M.; Kennedy A.; Lopez V.; Mendell J.R.; A roadmap to newborn screening for duchenne muscular dystrophy. Int J Neonatal Screen 2017,3(2),8","journal-title":"Int J Neonatal Screen"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/hmg\/ddl180","volume":"15","author":"Duan D.","year":"2006","unstructured":"Duan D.; Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Gene 2006,15(2),253-61","journal-title":"Hum Mol Gene"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/RRB.S13463","volume":"2011","author":"Duan D.","year":"2011","unstructured":"Duan D.; Duchenne muscular dystrophy gene therapy: Lost in translation? Res Rep Biol 2011,2011(2),31-42","journal-title":"Res Rep Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/humc.2015.006","volume":"26","author":"Duan D.","year":"2015","unstructured":"Duan D.; Duchenne muscular dystrophy gene therapy in the canine model. Hum Gene Ther Clin Dev 2015,26(1),57-69","journal-title":"Hum Gene Ther Clin Dev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/biomedicines2020149","volume":"2","author":"Wirth T.","year":"2014","unstructured":"Wirth T.; Yl\u00e4-Herttuala S.; Gene therapy used in cancer treatment. Biomedicines 2014,2(2),149-162","journal-title":"Biomedicines"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1517\/21678707.2016.1124039","volume":"4","author":"Yue Y.","year":"2016","unstructured":"Yue Y.; Binalsheikh I.M.; Leach S.B.; Domeier T.L.; Duan D.; Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy. Expert Opin Orphan Drugs 2016,4(2),169-183","journal-title":"Expert Opin Orphan Drugs"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jconrel.2015.08.001","volume":"215","author":"Mason D.","year":"2015","unstructured":"Mason D.; Chen Y-Z.; Krishnan H.V.; Sant S.; Cardiac gene therapy: Recent advances and future directions. J Control Release 2015,215,101-111","journal-title":"J Control Release"},{"key":"ref=15","first-page":"127","volume":"61","author":"Misra S.","year":"2013","unstructured":"Misra S.; Human gene therapy: a brief overview of the genetic revolution. J Assoc Physicians India 2013,61(2),127-133","journal-title":"J Assoc Physicians India"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1517\/14712598.2016.1114096","volume":"16","author":"Choong C.J.","year":"2016","unstructured":"Choong C.J.; Baba K.; Mochizuki H.; Gene therapy for neurological disorders. Expert Opin Biol Ther 2016,16(2),143-159","journal-title":"Expert Opin Biol Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15252\/emmm.201707573","volume":"9","author":"Aiuti A.","year":"2017","unstructured":"Aiuti A.; Roncarolo M.G.; Naldini L.; Gene therapy for ADA-SCID, the first marketing approval of an ex\u00a0vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med 2017,9(6),737-740","journal-title":"EMBO Mol Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/gt.2016.71","volume":"24","author":"Finer M.","year":"2017","unstructured":"Finer M.; Glorioso J.; A brief account of viral vectors and their promise for gene therapy. Gene Ther 2017,24(1),1-2","journal-title":"Gene Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1002\/emmm.201202287","volume":"5","author":"Kaufmann K.B.","year":"2013","unstructured":"Kaufmann K.B.; B\u00fcning H.; Galy A.; Schambach A.; Grez M.; Gene therapy on the move. EMBO Mol Med 2013,5(11),1642-1661","journal-title":"EMBO Mol Med"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.5772\/52702","author":"Li Q.","year":"2013","unstructured":"Li Q.; Verma A.; Zhu P.;  Gene therapy-tools and potential applications, Martin F (Ed)IntechOpen 2013","journal-title":"Gene therapy-tools and potential applications, Martin F (Ed)IntechOpen"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.molmed.2015.06.001","volume":"21","author":"O\u2019Connor D.M.","year":"2015","unstructured":"O\u2019Connor D.M.; Boulis N.M.; Gene therapy for neurodegenerative diseases. Trends Mol Med 2015,21(8),504-512","journal-title":"Trends Mol Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.4103\/1673-5374.250570","volume":"14","author":"Qu Y.","year":"2019","unstructured":"Qu Y.; Liu Y.; Noor A.F.; Tran J.; Li R.; Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases. Neural Regen Res 2019,14(6),931-938","journal-title":"Neural Regen Res"},{"key":"ref=23","first-page":"291","volume":"2","author":"Blaese M.","year":"1995","unstructured":"Blaese M.; Blankenstein T.; Brenner M.; Cohen-Haguenauer O.; Gansbacher B.; Russell S.; Sorrentino B.; Velu T.; Vectors in cancer therapy: how will they deliver? Cancer Gene Ther 1995,2(4),291-297","journal-title":"Cancer Gene Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/sj.mt.6300224","volume":"15","author":"Liu W.","year":"2007","unstructured":"Liu W.; Liu Z.; Cao X.; Cao Z.; Xue L.; Zhu F.; He X.; Li W.; Recombinant human foamy virus, a novel vector for neurological disorders gene therapy, drives production of GAD in cultured astrocytes. Mol Ther 2007,15(10),1834-1841","journal-title":"Mol Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.3390\/ijms20184388","volume":"20","author":"Cappella M.","year":"2019","unstructured":"Cappella M.; Ciotti C.; Cohen-Tannoudji M.; Biferi M.G.; Gene Therapy for ALS-A Perspective. Int J Mol Sci 2019,20(18),4388","journal-title":"Int J Mol Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3390\/ijms20061514","volume":"20","author":"Giau V.V.","year":"2019","unstructured":"Giau V.V.; Senanarong V.; Bagyinszky E.; An S.S.A.; Kim S.; Analysis of 50 neurodegenerative genes in clinically diagnosed early-onset Alzheimer\u2019s disease. Int J Mol Sci 2019,20(6),1514","journal-title":"Int J Mol Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2174\/187152731307141015122638","volume":"13","author":"Karim S","year":"2014","unstructured":"Karim S; Mirza Z, A; Kamal M; The role of viruses in neurodegenerative and neurobehavioral diseases. CNS Neurol Dis Drug Targ 2014,13(7),1213-23","journal-title":"CNS Neurol Dis Drug Targ"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"E222","DOI":"10.3390\/brainsci8120222","volume":"8","author":"Garc\u00eda J.C.","year":"2018","unstructured":"Garc\u00eda J.C.; Bustos R.H.; The genetic diagnosis of neurodegenerative diseases and therapeutic perspectives. Brain Sci 2018,8(12),E222","journal-title":"Brain Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.32474\/OJNBD.2018.01.000103","volume":"1","author":"Ashim K","year":"2018","unstructured":"Ashim K; Tridip C.; Progresses in gene therapy of neurodegenerative disorders. On J Neur Br Disord 2018,1(1),1-18","journal-title":"On J Neur Br Disord"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm1113","volume":"10","author":"Forman M.S.","year":"2004","unstructured":"Forman M.S.; Trojanowski J.Q.; Lee V.M.; Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004,10(10),1055-1063","journal-title":"Nat Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","volume":"16","author":"Sudhakar V.","year":"2019","unstructured":"Sudhakar V.; Richardson R.M.; Gene therapy for neurodegenerative diseases. Neurotherapeutics 2019,16(1),166-175","journal-title":"Neurotherapeutics"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1089\/hum.2017.160","volume":"28","author":"Piguet F.","year":"2017","unstructured":"Piguet F.; Alves S.; Cartier N.; Clinical gene therapy for neurodegenerative diseases: past, present, and future. Hum Gene Ther 2017,28(11),988-1003","journal-title":"Hum Gene Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2741\/E607","volume":"5","author":"Gan Y.","year":"2013","unstructured":"Gan Y.; Jing Z.; Stetler R.A.; Cao G.; Gene delivery with viral vectors for cerebrovascular diseases. Front Biosci (Elite Ed) 2013,5,188-203","journal-title":"Front Biosci (Elite Ed)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s13311-014-0299-5","volume":"11","author":"Maguire C.A.","year":"2014","unstructured":"Maguire C.A.; Ramirez S.H.; Merkel S.F.; Sena-Esteves M.; Breakefield X.O.; Gene therapy for the nervous system: Challenges and new strategies. Neurotherapeutics 2014,11(4),817-839","journal-title":"Neurotherapeutics"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"16034","DOI":"10.1038\/mtm.2016.34","volume":"3","author":"Kumar S.R.","year":"2016","unstructured":"Kumar S.R.; Markusic D.M.; Biswas M.; High K.A.; Herzog R.W.; Clinical development of gene therapy: Results and lessons from recent successes. Mol Ther Methods Clin Dev 2016,3,16034","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.7150\/thno.21254","volume":"8","author":"Dong X.","year":"2018","unstructured":"Dong X.; Current strategies for brain drug delivery. Theranostics 2018,8(6),1481-1493","journal-title":"Theranostics"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"e0158281","DOI":"10.1371\/journal.pone.0158281","volume":"11","author":"Gholizadeh-Ghaleh Aziz S","year":"2016","unstructured":"Gholizadeh-Ghaleh Aziz S; Pashaei-Asl F; Fardyazar Z; Pashaiasl M.; Isolation, characterization, cryopreservation of human amniotic stem cells and differentiation to osteogenic and adipogenic cells. PloS One 2016,11(7),e0158281","journal-title":"PloS One"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/cbin.10218","volume":"38","author":"Zare S.","year":"2014","unstructured":"Zare S.; Zarei M.A.; Ghadimi T.; Fathi F.; Jalili A.; Hakhamaneshi M.S.; Isolation, cultivation and transfection of human keratinocytes. Cell Biol Int 2014,38(4),444-451","journal-title":"Cell Biol Int"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1021\/acschemneuro.0c00052","volume":"11","author":"Farahzadi R.","year":"2020","unstructured":"Farahzadi R.; Fathi E.; Vietor I.; Mesenchymal stem cells could be considered as a candidate for further studies in cell-based therapy of Alzheimer\u2019s disease via targeting the signaling pathways. ACS Chem Neurosci 2020,11(10),1424-1435","journal-title":"ACS Chem Neurosci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.21037\/sci.2019.06.04","volume":"6","author":"Rajabzadeh N.","year":"2019","unstructured":"Rajabzadeh N.; Fathi E.; Farahzadi R.; Stem cell-based regenerative medicine. Stem Cell Investig 2019,6,19","journal-title":"Stem Cell Investig"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"pp. 271","DOI":"10.1007\/7854_2014_310","author":"Van der Perren A.","year":"2014","unstructured":"Van der Perren A.; Van den Haute C.; Baekelandt V.;  Behavioral neurobiology of huntington\u2019s disease and Parkinson\u2019s disease Springer 2014,pp. 271-301","journal-title":"Behavioral neurobiology of huntington\u2019s disease and Parkinson\u2019s disease Springer"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0168-0102(01)00254-1","volume":"41","author":"Shastry B.S.","year":"2001","unstructured":"Shastry B.S.; Parkinson disease: Etiology, pathogenesis and future of gene therapy. Neurosci Res 2001,41(1),5-12","journal-title":"Neurosci Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ymthe.2018.02.029","volume":"26","author":"Chang J.L.","year":"2018","unstructured":"Chang J.L.; Hinrich A.J.; Roman B.; Norrbom M.; Rigo F.; Marr R.A.; Norstrom E.M.; Hastings M.L.; Targeting amyloid-\u03b2 precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-\u03b2 production. Mol Ther 2018,26(6),1539-1551","journal-title":"Mol Ther"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7150\/jbm.26783","volume":"3","author":"Chaudhary A.","year":"2018","unstructured":"Chaudhary A.; Maurya P.K.; Yadav B.S.; Singh S.; Mani A.; Current therapeutic targets for Alzheimer\u2019s disease. J Biomed (Syd) 2018,3,74-84","journal-title":"J Biomed (Syd)"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"Pringsheim T.","year":"2012","unstructured":"Pringsheim T.; Wiltshire K.; Day L.; Dykeman J.; Steeves T.; Jette N.; The incidence and prevalence of Huntington\u2019s disease: A systematic review and meta-analysis. Mov Disord 2012,27(9),1083-1091","journal-title":"Mov Disord"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1750-1326-8-28","volume":"8","author":"Chen S.","year":"2013","unstructured":"Chen S.; Sayana P.; Zhang X.; Le W.; Genetics of amyotrophic lateral sclerosis: An update. Mol Neurodegener 2013,8(1),28","journal-title":"Mol Neurodegener"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/gt.2012.10","volume":"19","author":"Lai Y.","year":"2012","unstructured":"Lai Y.; Duan D.; Progress in gene therapy of dystrophic heart disease. Gene Ther 2012,19(6),678-685","journal-title":"Gene Ther"},{"key":"ref=48","first-page":"361","volume":"19","author":"Hosseini A.","year":"2017","unstructured":"Hosseini A.; Estiri H.; Niaki H.A.; Multiple sclerosis gene therapy using recombinant viral vectors: Overexpression of IL-4, IL-10 and leukemia inhibitory factor in wharton\u2019s jelly stem cells in the eae mice model. Cell 2017,19(3),361","journal-title":"Cell"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ijpharm.2017.12.010","volume":"536","author":"Hamana A.","year":"2018","unstructured":"Hamana A.; Takahashi Y.; Tanioka A.; Nishikawa M.; Takakura Y.; Safe and effective interferon-beta gene therapy for the treatment of multiple sclerosis by regulating biological activity through the design of interferon-beta-galectin-9 fusion proteins. Int J Pharm 2018,536(1),310-317","journal-title":"Int J Pharm"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/JND-140066","volume":"2","author":"Burch P.M.","year":"2015","unstructured":"Burch P.M.; Pogoryelova O.; Goldstein R.; Bennett D.; Guglieri M.; Straub V.; Bushby K.; Lochm\u00fcller H.; Morris C.; Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy. J Neuromuscul Dis 2015,2(3),241-255","journal-title":"J Neuromuscul Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11892-008-0075-1","volume":"8","author":"Mata M.","year":"2008","unstructured":"Mata M.; Chattopadhyay M.; Fink D.J.; Gene therapy for the treatment of diabetic neuropathy. Curr Diab Rep 2008,8(6),431-436","journal-title":"Curr Diab Rep"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/genes5030586","volume":"5","author":"Sandford E.","year":"2014","unstructured":"Sandford E.; Burmeister M.; Genes and genetic testing in hereditary ataxias. Genes (Basel) 2014,5(3),586-603","journal-title":"Genes (Basel)"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1093\/hmg\/ddr110","volume":"20","author":"Bowers W.J.","year":"2011","unstructured":"Bowers W.J.; Breakefield X.O.; Sena-Esteves M.; Genetic therapy for the nervous system. Hum Mol Genet 2011,20(R1),R28-R41","journal-title":"Hum Mol Genet"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40824-019-0156-z","volume":"23","author":"Sung Y.K.","year":"2019","unstructured":"Sung Y.K.; Kim S.W.; Recent advances in the development of gene delivery systems. Biomater Res 2019,23(1),8","journal-title":"Biomater Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/2277-9175.98152","volume":"1","author":"Nayerossadat N.","year":"2012","unstructured":"Nayerossadat N.; Maedeh T.; Ali P.A.; Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 2012,1,27","journal-title":"Adv Biomed Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jgm.707","volume":"7","author":"Deglon N","year":"2005","unstructured":"Deglon N; Hantraye P; Viral vectors as tools to model and treat neurodegenerative disorders. J Gene Med 2005,7(5),530-9","journal-title":"J Gene Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.gt.3302690","volume":"13","author":"Raoul C.","year":"2006","unstructured":"Raoul C.; Barker S.D.; Aebischer P.; Viral-based modelling and correction of neurodegenerative diseases by RNA interference. Gene Ther 2006,13(6),487-495","journal-title":"Gene Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"GE01","DOI":"10.7860\/JCDR\/2015\/10443.5394","volume":"9","author":"Ramamoorth M.","year":"2015","unstructured":"Ramamoorth M.; Narvekar A.; Non viral vectors in gene therapy- an overview. J Clin Diagn Res 2015,9(1),GE01-GE06","journal-title":"J Clin Diagn Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrg3763","volume":"15","author":"Yin H.","year":"2014","unstructured":"Yin H.; Kanasty R.L.; Eltoukhy A.A.; Vegas A.J.; Dorkin J.R.; Anderson D.G.; Non-viral vectors for gene-based therapy. Nat Rev Genet 2014,15(8),541-555","journal-title":"Nat Rev Genet"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0971-6866.112870","volume":"19","author":"Mali S.","year":"2013","unstructured":"Mali S.; Delivery systems for gene therapy. Indian J Hum Genet 2013,19(1),3-8","journal-title":"Indian J Hum Genet"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3389\/fphar.2019.00724","volume":"10","author":"Ingusci S.","year":"2019","unstructured":"Ingusci S.; Verlengia G.; Soukupova M.; Zucchini S.; Simonato M.; Gene therapy tools for brain diseases. Front Pharmacol 2019,10,724","journal-title":"Front Pharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1006\/mthe.2001.0475","volume":"4","author":"Varga C.M.","year":"2001","unstructured":"Varga C.M.; Hong K.; Lauffenburger D.A.; Quantitative analysis of synthetic gene delivery vector design properties. Mol Ther 2001,4(5),438-446","journal-title":"Mol Ther"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1080\/17425247.2016.1188802","volume":"13","author":"Jayant R.D.","year":"2016","unstructured":"Jayant R.D.; Sosa D.; Kaushik A.; Atluri V.; Vashist A.; Tomitaka A.; Nair M.; Current status of non-viral gene therapy for CNS disorders. Expert Opin Drug Deliv 2016,13(10),1433-1445","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijpharm.2013.11.041","volume":"459","author":"Ibraheem D.","year":"2014","unstructured":"Ibraheem D.; Elaissari A.; Fessi H.; Gene therapy and DNA delivery systems. Int J Pharm 2014,459(1-2),70-83","journal-title":"Int J Pharm"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bbagen.2009.05.013","volume":"1790","author":"Uchida M.","year":"2009","unstructured":"Uchida M.; Li X.W.; Mertens P.; Alpar H.O.; Transfection by particle bombardment: delivery of plasmid DNA into mammalian cells using gene gun. Biochim Biophys Acta 2009,1790(8),754-764","journal-title":"Biochim Biophys Acta"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1021\/cr800409e","volume":"109","author":"Mintzer M.A.","year":"2009","unstructured":"Mintzer M.A.; Simanek E.E.; Nonviral vectors for gene delivery. Chem Rev 2009,109(2),259-302","journal-title":"Chem Rev"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1208\/s12248-009-9143-y","volume":"11","author":"Al-Dosari M.S.","year":"2009","unstructured":"Al-Dosari M.S.; Gao X.; Nonviral gene delivery: Principle, limitations, and recent progress. AAPS J 2009,11(4),671-681","journal-title":"AAPS J"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.3390\/ijms20215491","volume":"20","author":"Patil S.","year":"2019","unstructured":"Patil S.; Gao Y-G.; Lin X.; Li Y.; Dang K.; Tian Y.; Zhang W.J.; Jiang S.F.; Qadir A.; Qian A.R.; The development of functional non-viral vectors for gene delivery. Int J Mol Sci 2019,20(21),5491","journal-title":"Int J Mol Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.7150\/thno.4306","volume":"2","author":"Sirsi S.R.","year":"2012","unstructured":"Sirsi S.R.; Borden M.A.; Advances in ultrasound mediated gene therapy using microbubble contrast agents. Theranostics 2012,2(12),1208-1222","journal-title":"Theranostics"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"11854","DOI":"10.1073\/pnas.182412299","volume":"99","author":"Gao G-P.","year":"2002","unstructured":"Gao G-P.; Alvira M.R.; Wang L.; Calcedo R.; Johnston J.; Wilson J.M.; Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002,99(18),11854-11859","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","volume":"1","author":"Samulski R.J.","year":"2014","unstructured":"Samulski R.J.; Muzyczka N.; AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 2014,1(1),427-451","journal-title":"Annu Rev Virol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/hum.2015.025","volume":"26","author":"Hastie E.","year":"2015","unstructured":"Hastie E.; Samulski R.J.; Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success a personal perspective. Hum Gene Ther 2015,26(5),257-265","journal-title":"Hum Gene Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"Naso M.F.","year":"2017","unstructured":"Naso M.F.; Tomkowicz B.; Perry W.L.; Strohl W.R.; Adeno-Associated Virus (AAV) as a vector for gene therapy. BioDrugs 2017,31(4),317-334","journal-title":"BioDrugs"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","volume":"58","author":"Escors D.","year":"2010","unstructured":"Escors D.; Breckpot K.; Lentiviral vectors in gene therapy: Their current status and future potential. Arch Immunol Ther Exp 2010,58(2),107-119","journal-title":"Arch Immunol Ther Exp"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nn1531","volume":"8","author":"Singer O.","year":"2005","unstructured":"Singer O.; Marr R.A.; Rockenstein E.; Crews L.; Coufal N.G.; Gage F.H.; Verma I.M.; Masliah E.; Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005,8(10),1343-1349","journal-title":"Nat Neurosci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1517\/14712598.7.12.1853","volume":"7","author":"Spencer B.","year":"2007","unstructured":"Spencer B.; Rockenstein E.; Crews L.; Marr R.; Masliah E.; Novel strategies for Alzheimer\u2019s disease treatment. Expert Opin Biol Ther 2007,7(12),1853-1867","journal-title":"Expert Opin Biol Ther"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","volume":"34","author":"O\u2019Brien R.J.","year":"2011","unstructured":"O\u2019Brien R.J.; Wong P.C.; Amyloid precursor protein processing and Alzheimer\u2019s disease. Annu Rev Neurosci 2011,34,185-204","journal-title":"Annu Rev Neurosci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","volume":"120","author":"Choudhury S.R.","year":"2017","unstructured":"Choudhury S.R.; Hudry E.; Maguire C.A.; Sena-Esteves M.; Breakefield X.O.; Grandi P.; Viral vectors for therapy of neurologic diseases. Neuropharmacology 2017,120,63-80","journal-title":"Neuropharmacology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","volume":"343","author":"Machida Y.","year":"2006","unstructured":"Machida Y.; Okada T.; Kurosawa M.; Oyama F.; Ozawa K.; Nukina N.; rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun 2006,343(1),190-197","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/hum.2017.199","volume":"29","author":"Pfister E.L.","year":"2018","unstructured":"Pfister E.L.; DiNardo N.; Mondo E.; Borel F.; Conroy F.; Fraser C.; Gernoux G.; Han X.; Hu D.; Johnson E.; Kennington L.; Liu P.; Reid S.J.; Sapp E.; Vodicka P.; Kuchel T.; Morton A.J.; Howland D.; Moser R.; Sena-Esteves M.; Gao G.; Mueller C.; DiFiglia M.; Aronin N.; Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of Huntington\u2019s disease. Hum Gene Ther 2018,29(6),663-673","journal-title":"Hum Gene Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1146\/annurev-virology-031413-085427","volume":"1","author":"Bush D.L.","year":"2014","unstructured":"Bush D.L.; Vogt V.M.; \n                        In vitro assembly of retroviruses. Annu Rev Virol 2014,1(1),561-580","journal-title":"Annu Rev Virol"},{"key":"ref=82","doi-asserted-by":"publisher","DOI":"10.5772\/62885","author":"Saxena S.K.","year":"2016","unstructured":"Saxena S.K.; Chitti S.V.P.;  Advances in molecular retrovirology Intechopen 2016","journal-title":"Advances in molecular retrovirology Intechopen"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/brain\/120.7.1245","volume":"120","author":"Kennedy P.G.","year":"1997","unstructured":"Kennedy P.G.; Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. Brain 1997,120(Pt 7),1245-1259","journal-title":"Brain"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"E74","DOI":"10.3390\/diseases6030074","volume":"6","author":"Artusi S.","year":"2018","unstructured":"Artusi S.; Miyagawa Y.; Goins W.F.; Cohen J.B.; Glorioso J.C.; Herpes simplex virus vectors for gene transfer to the central nervous system. Diseases 2018,6(3),E74","journal-title":"Diseases"},{"key":"ref=85","first-page":"71","volume":"7","author":"Goss J.R.","year":"2014","unstructured":"Goss J.R.; Krisky D.; Wechuck J.; Wolfe D.; Herpes simplex virus-based nerve targeting gene therapy in pain management. J Pain Res 2014,7,71-79","journal-title":"J Pain Res"},{"key":"ref=86","first-page":"123","volume":"4","author":"Manservigi R.","year":"2010","unstructured":"Manservigi R.; Argnani R.; Marconi P.; HSV recombinant vectors for gene therapy. Open Virol J 2010,4,123-156","journal-title":"Open Virol J"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/diseases6020042","volume":"6","author":"Lundstrom K.","year":"2018","unstructured":"Lundstrom K.; Viral vectors in gene therapy. Diseases 2018,6(2),42","journal-title":"Diseases"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mcn.2016.01.006","volume":"72","author":"Thakur V.","year":"2016","unstructured":"Thakur V.; Gonzalez M.; Pennington K.; Chattopadhyay M.; Viral vector mediated continuous expression of interleukin-10 in DRG alleviates pain in type 1 diabetic animals. Mol Cell Neurosci 2016,72,46-53","journal-title":"Mol Cell Neurosci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.virusres.2015.08.015","volume":"216","author":"Lundstrom K.","year":"2016","unstructured":"Lundstrom K.; Alphavirus vectors as tools in neuroscience and gene therapy. Virus Res 2016,216,16-25","journal-title":"Virus Res"},{"key":"ref=90","first-page":"28","volume":"4","author":"Lundstrom K.","year":"2002","unstructured":"Lundstrom K.; Alphavirus-based vaccines. Curr Opin Mol Ther 2002,4(1),28-34","journal-title":"Curr Opin Mol Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"pp. 51","DOI":"10.1007\/978-1-60327-317-6_4","author":"Lundstrom K.","year":"2009","unstructured":"Lundstrom K.;  G Protein-coupled receptors in drug discovery Springer 2009,pp. 51-66","journal-title":"G Protein-coupled receptors in drug discovery Springer"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/sj.gt.3301122","volume":"7","author":"Wahlfors J.J.","year":"2000","unstructured":"Wahlfors J.J.; Zullo S.A.; Loimas S.; Nelson D.M.; Morgan R.A.; Evaluation of recombinant alphaviruses as vectors in gene therapy. Gene Ther 2000,7(6),472-480","journal-title":"Gene Ther"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1111\/bph.13208","volume":"172","author":"Harrison I.F.","year":"2015","unstructured":"Harrison I.F.; Crum W.R.; Vernon A.C.; Dexter D.T.; Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson\u2019s is associated with histone acetylation and up-regulation of neurotrophic factors. Br J Pharmacol 2015,172(16),4200-4215","journal-title":"Br J Pharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms17060904","volume":"17","author":"Sarkar S.","year":"2016","unstructured":"Sarkar S.; Raymick J.; Imam S.; Neuroprotective and therapeutic strategies against Parkinson\u2019s disease: recent perspectives. Int J Mol Sci 2016,17(6),904","journal-title":"Int J Mol Sci"},{"key":"ref=95","author":"Triarhou L.C.","year":"2013","unstructured":"Triarhou L.C.;  Madame Curie Bioscience Database Landes Bioscience 2013","journal-title":"Madame Curie Bioscience Database Landes Bioscience"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1006\/exnr.1996.6389","volume":"144","author":"Bowers W.J.","year":"1997","unstructured":"Bowers W.J.; Howard D.F.; Federoff H.J.; Gene therapeutic strategies for neuroprotection: implications for Parkinson\u2019s disease. Exp Neurol 1997,144(1),58-68","journal-title":"Exp Neurol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JPD-181331","volume":"8","author":"Axelsen T.M.","year":"2018","unstructured":"Axelsen T.M.; Woldbye D.P.D.; Gene therapy for Parkinson\u2019s disease, an update. J Parkinsons Dis 2018,8(2),195-215","journal-title":"J Parkinsons Dis"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"p. 255","DOI":"10.5772\/17420","author":"Douglas M.","year":"2011","unstructured":"Douglas M.; Hazlehurst J.;  Gene therapy for Parkinson\u2019s disease Towards new therapies for Parkinson's disease Intechopen 2011,p. 255","journal-title":"Gene therapy for Parkinson\u2019s disease Towards new therapies for Parkinson's disease Intechopen"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"LeWitt P.A.","year":"2011","unstructured":"LeWitt P.A.; Rezai A.R.; Leehey M.A.; Ojemann S.G.; Flaherty A.W.; Eskandar E.N.; Kostyk S.K.; Thomas K.; Sarkar A.; Siddiqui M.S.; Tatter S.B.; Schwalb J.M.; Poston K.L.; Henderson J.M.; Kurlan R.M.; Richard I.H.; Van Meter L.; Sapan C.V.; During M.J.; Kaplitt M.G.; Feigin A.; AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011,10(4),309-319","journal-title":"Lancet Neurol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1586\/14737175.3.6.729","volume":"3","author":"During M.J.","year":"2003","unstructured":"During M.J.; Gene therapy in Parkinson\u2019s disease. Expert Rev Neurother 2003,3(6),729-732","journal-title":"Expert Rev Neurother"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.expneurol.2017.10.001","volume":"298","author":"Francardo V","year":"2017","unstructured":"Francardo V; Schmitz Y; Sulzer D; Cenci MA; Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease Exp Neurol 2017,298(Pt B),137-47","journal-title":"Exp Neurol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fnana.2017.00040","volume":"11","author":"Segura-Aguilar J.","year":"2017","unstructured":"Segura-Aguilar J.; Commentary: gene therapy: A promising approach for neuroprotection in Parkinson\u2019s Disease? Front Neuroanat 2017,11,40","journal-title":"Front Neuroanat"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"757305","DOI":"10.1155\/2012\/757305","volume":"2012","author":"Denyer R.","year":"2012","unstructured":"Denyer R.; Douglas M.R.; Gene therapy for Parkinson\u2019s disease. Parkinsons Dis 2012,2012,757305","journal-title":"Parkinsons Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"Serrano-Pozo A","year":"2011","unstructured":"Serrano-Pozo A; Frosch MP; Masliah E; Hyman BT; Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011,1(1),a006189","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1601-183X.2007.00378.x","volume":"7","author":"Schindowski K.","year":"2008","unstructured":"Schindowski K.; Belarbi K.; Bu\u00e9e L.; Neurotrophic factors in Alzheimer\u2019s disease: role of axonal transport. Genes Brain Behav 2008,7(Suppl 1),43-56","journal-title":"Genes Brain Behav"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/jamaneurol.2015.1807","volume":"72","author":"Tuszynski M.H.","year":"2015","unstructured":"Tuszynski M.H.; Yang J.H.; Barba D.; U H.S.; Bakay R.A.; Pay M.M.; Masliah E.; Conner J.M.; Kobalka P.; Roy S.; Nagahara A.H.; Nerve growth factor gene therapy: Activation of neuronal responses in Alzheimer Disease. JAMA Neurol 2015,72(10),1139-1147","journal-title":"JAMA Neurol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1212\/WNL.52.7.1427","volume":"52","year":"1999","unstructured":"A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 1999,52(7),1427-1433","journal-title":"Neurology"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fnins.2010.00032","volume":"4","author":"Henriques A.","year":"2010","unstructured":"Henriques A.; Pitzer C.; Schneider A.; Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: Where do we stand? Front Neurosci 2010,4,32","journal-title":"Front Neurosci"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1371\/journal.pone.0000689","volume":"2","author":"Suzuki M.","year":"2007","unstructured":"Suzuki M.; McHugh J.; Tork C.; Shelley B.; Klein S.M.; Aebischer P.; Svendsen C.N.; GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One 2007,2(8),e689","journal-title":"PLoS One"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/0470870834.ch5","volume":"231","author":"Bohn MC","year":"2000","unstructured":"Bohn MC; Connor B; Kozlowski DA; Mohajeri MH; Gene transfer for neuroprotection in animal models of Parkinson's disease and amyotrophic lateral sclerosis. Novartis Found Symp 2000,231,70-89","journal-title":"Novartis Found Symp"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1523\/JNEUROSCI.22-16-06920.2002","volume":"22","author":"Wang L.J.","year":"2002","unstructured":"Wang L.J.; Lu Y.Y.; Muramatsu S.; Ikeguchi K.; Fujimoto K.; Okada T.; Mizukami H.; Matsushita T.; Hanazono Y.; Kume A.; Nagatsu T.; Ozawa K.; Nakano I.; Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 2002,22(16),6920-6928","journal-title":"J Neurosci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/mt.2008.60","volume":"16","author":"Dodge JC","year":"2008","unstructured":"Dodge JC; Haidet AM; Yang W; Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Therap 2008,16(6),1056-64","journal-title":"Mol Therap"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/mt.2010.206","volume":"18","author":"Dodge JC","year":"2010","unstructured":"Dodge JC; Treleaven CM; Fidler JA; AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Therap 2010,18(12),2075-84","journal-title":"Mol Therap"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fnmol.2016.00056","volume":"9","author":"Stoica L.","year":"2016","unstructured":"Stoica L.; Sena-Esteves M.; Adeno associated viral vector delivered rnai for gene therapy of SOD1 amyotrophic lateral sclerosis. Front Mol Neurosci 2016,9(56),56","journal-title":"Front Mol Neurosci"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fneur.2019.00835","volume":"10","author":"Gouel F.","year":"2019","unstructured":"Gouel F.; Rolland A-S.; Devedjian J-C.; Burnouf T.; Devos D.; Past and future of neurotrophic growth factors therapies in ALS: From single neurotrophic growth factor to stem cells and human platelet lysates. Front Neurol 2019,10(835),835","journal-title":"Front Neurol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1007\/s00018-013-1415-0","volume":"70","author":"Pandya R.S.","year":"2013","unstructured":"Pandya R.S.; Zhu H.; Li W.; Bowser R.; Friedlander R.M.; Wang X.; Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci 2013,70(24),4729-4745","journal-title":"Cell Mol Life Sci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/gt.2015.102","volume":"22","author":"Glorioso J.C.","year":"2015","unstructured":"Glorioso J.C.; Cohen J.B.; Carlisle D.L.; Munoz-Sanjuan I.; Friedlander R.M.; Moving toward a gene therapy for Huntington\u2019s disease. Gene Ther 2015,22(12),931-933","journal-title":"Gene Ther"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ymthe.2004.02.016","volume":"9","author":"Kells A.P.","year":"2004","unstructured":"Kells A.P.; Fong D.M.; Dragunow M.; During M.J.; Young D.; Connor B.; AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 2004,9(5),682-688","journal-title":"Mol Ther"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.phrs.2009.10.002","volume":"61","author":"Lim S.T.","year":"2010","unstructured":"Lim S.T.; Airavaara M.; Harvey B.K.; Viral vectors for neurotrophic factor delivery: A gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 2010,61(1),14-26","journal-title":"Pharmacol Res"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"753548","DOI":"10.1155\/2012\/753548","volume":"2012","author":"Lauterbach E.C.","year":"2012","unstructured":"Lauterbach E.C.; Fontenelle L.F.; Teixeira A.L.; The neuroprotective disease-modifying potential of psychotropics in Parkinson\u2019s disease. Parkinsons Dis 2012,2012,753548","journal-title":"Parkinsons Dis"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1523\/JNEUROSCI.4182-09.2010","volume":"30","author":"Garcia P.","year":"2010","unstructured":"Garcia P.; Youssef I.; Utvik J.K.; Florent-B\u00e9chard S.; Barth\u00e9l\u00e9my V.; Malaplate-Armand C.; Kriem B.; Stenger C.; Koziel V.; Olivier J.L.; Escanye M.C.; Hanse M.; Allouche A.; Desb\u00e8ne C.; Yen F.T.; Bjerkvig R.; Oster T.; Niclou S.P.; Pillot T.; Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer\u2019s disease. J Neurosci 2010,30(22),7516-7527","journal-title":"J Neurosci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.tips.2006.10.002","volume":"27","author":"Simonato M.","year":"2006","unstructured":"Simonato M.; Tongiorgi E.; Kokaia M.; Angels and demons: Neurotrophic factors and epilepsy. Trends Pharmacol Sci 2006,27(12),631-638","journal-title":"Trends Pharmacol Sci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","volume":"11","author":"Bathina S.","year":"2015","unstructured":"Bathina S.; Das U.N.; Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci 2015,11(6),1164-1178","journal-title":"Arch Med Sci"},{"key":"ref=124","author":"Noe F.M.","year":"2012","unstructured":"Noe F.M.; S\u00f8rensen A.T.; Kokaia M.; Vezzani A.;  Jasper\u2019s basic mechanisms of the epilepsies (4 ed), US: National Center for Biotechnology Information Available at: ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"\/\/www.ncbi.nlm.nih.gov\/books\/NBK50785\/\">\/\/www.ncbi.nlm.nih.gov\/books\/NBK50785\/2012","journal-title":"Jasper\u2019s basic mechanisms of the epilepsies (4 ed), US: National Center for Biotechnology Information"},{"key":"ref=125","author":"S\u00f8rensen AT","unstructured":"S\u00f8rensen AT; Kokaia M; Vezzani A; Gene therapy of focal onset epilepsy using adeno-associated virus vector-mediated overexpression of neuropeptide Y.  In Jasper\u2019s basic mechanisms of the epilepsies. 4 ed, Noebels JL, Avoli M, Rogawski MA, et al. Editors. 2012. Available at: ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"\/\/www.ncbi.nlm.nih.gov\/books\/NBK98184\/\">\/\/www.ncbi.nlm.nih.gov\/books\/NBK 98184\/"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3389\/fphys.2019.00486","volume":"10","author":"P\u00f6yh\u00f6nen S.","year":"2019","unstructured":"P\u00f6yh\u00f6nen S.; Er S.; Domanskyi A.; Airavaara M.; Effects of neurotrophic factors in glial cells in the central nervous system: Expression and properties in neurodegeneration and injury. Front Physiol 2019,10(486),486","journal-title":"Front Physiol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.expneurol.2011.10.003","volume":"244","author":"Weinberg M.S.","year":"2013","unstructured":"Weinberg M.S.; McCown T.J.; Current prospects and challenges for epilepsy gene therapy. Exp Neurol 2013,244,27-35","journal-title":"Exp Neurol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1093\/brain\/awq219","volume":"133","author":"Woldbye D.P.","year":"2010","unstructured":"Woldbye D.P.; \u00c4ngehagen M.; G\u00f8tzsche C.R.; Elbr\u00f8nd-Bek H.; S\u00f8rensen A.T.; Christiansen S.H.; Olesen M.V.; Nikitidou L.; Hansen T.V.; Kanter-Schlifke I.; Kokaia M.; Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain 2010,133(9),2778-2788","journal-title":"Brain"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/epi.12000","volume":"54","author":"S\u00f8rensen A.T.","year":"2013","unstructured":"S\u00f8rensen A.T.; Kokaia M.; Novel approaches to epilepsy treatment. Epilepsia 2013,54(1),1-10","journal-title":"Epilepsia"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0006-8993(02)02923-2","volume":"947","author":"Zhang W.R.","year":"2002","unstructured":"Zhang W.R.; Sato K.; Iwai M.; Nagano I.; Manabe Y.; Abe K.; Therapeutic time window of adenovirus-mediated GDNF gene transfer after transient middle cerebral artery occlusion in rat. Brain Res 2002,947(1),140-145","journal-title":"Brain Res"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1161\/01.STR.29.7.1417","volume":"29","author":"Kitagawa H.","year":"1998","unstructured":"Kitagawa H.; Hayashi T.; Mitsumoto Y.; Koga N.; Itoyama Y.; Abe K.; Reduction of ischemic brain injury by topical application of glial cell line-derived neurotrophic factor after permanent middle cerebral artery occlusion in rats. Stroke 1998,29(7),1417-1422","journal-title":"Stroke"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12987-019-0139-4","volume":"16","author":"Katt M.E.","year":"2019","unstructured":"Katt M.E.; Mayo L.N.; Ellis S.E.; Mahairaki V.; Rothstein J.D.; Cheng L.; Searson P.C.; The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model. Fluids Barriers CNS 2019,16(1),20","journal-title":"Fluids Barriers CNS"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185986","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185986\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T10:04:07Z","timestamp":1637057047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185986\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":132,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523220999200917114101","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}